Biomea Fusion BMEA 深 沪
等待开盘 11-03 09:30:00 美东时间
1.36
+0.030
+2.26%
华盛通- 最 高1.38
- 今 开1.36
- 成交量 81.82万股
- 最 低 1.31
- 昨 收 1.33
- 总市值 8093.16万
- 52周最高 8.2825
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.2905
- 委 比 75.83%
- 总股本 5950.85万
- 历史最高 43.69
- 量 比 0.47
- 振 幅 5.26%
- 历史最低 1.2905
- 每 手 1
- 风险率 1.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Biomea Fusion’s BMF-650: A New Hope in Obesity Treatment?
Biomea Fusion Inc (($BMEA)) announced an update on their ongoing clinical study...
11-01 00:30
Biomea Fusion to Present Poster Presentations at ObesityWeek®2025
Biomea Fusion, Inc. will present preclinical data for BMF-650, an oral GLP-1 receptor agonist, and combination data for icovamenib with semaglutide at ObesityWeek® 2025. BMF-650 and icovamenib are part of Biomea’s portfolio targeting diabetes and obesity. The abstracts will be published in the Obesity journal supplement.
10-30 12:00
Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
<p>Biomea Fusion公司宣布，其用于治疗肥胖的下一代口服小分子GLP-1受体激动剂BMF-650已进入一期临床试验。首位患者已接受剂量，预计2026年上半年公布初期数据。在肥胖猴子模型中，BMF-650展示了显著的体重减轻和食物摄入减少，且耐受性良好。公司期望BMF-650凭借更高的生物利用度和一致的血浆暴露，为肥胖患者提供更有效的代谢效益。</p>
10-27 12:00
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series
Biomea Fusion will participate in Citi’s SMID Biotech fireside chat on October 23. The event will be live streamed with a replay available afterward. Biomea, focused on diabetes and obesity therapies, is developing icovamenib and BMF-650 to address metabolic disorders. Visit their website or follow them on LinkedIn, X, and Facebook for updates.
10-21 23:05
Nasdaq Tumbles 200 Points; Trilogy Metals Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Nasdaq Composite fall...
10-08 00:29
Dow Jumps Over 100 Points; McCormick Earnings Top Views
U.S. stocks traded higher this morning, with the Dow Jones index gaining more t...
10-07 22:20
Biomea Fusion announces pricing of public offering of securities
Biomea Fusion (NASDAQ:BMEA) announced the pricing of its public offering for gross proceeds of $25 million. The offer consists of 11.19M shares of its common stock and accompanying warrants to purchas...
10-07 20:26
Biomea Fusion Announces Proposed Public Offering Of Securities; No Size Or Amount Disclosed
Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants
10-07 04:18
Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations
Biomea Fusion announced positive 52-week results from its Phase II COVALENT-111 study for icovamenib, showing a 1.8% placebo-adjusted reduction in HbA1c in severe insulin-deficient diabetes patients and those on GLP-1 therapy. The drug demonstrated durability of effect up to 9 months after treatment and was generally well-tolerated. Phase II trials for severe insulin-deficient and GLP-1-failing diabetes patients are expected to begin by Q4 2025.
10-06 20:03
美股大行评级 | 潜在涨幅1176.6%！Ascendiant Capital上调Society Pass目标价至18美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从15美元升至18美元；Ascendiant Capital：维持Surgepays"买入"评级，目标价从9美元升至9.5美元
10-06 08:35
